Asset Details
Do you wish to reserve the book?
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Do you wish to request the book?
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
2025
Overview
Background
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is difficult to manage due to the heterogeneous disease course. There is a high need for new biomarkers to identify patients at high risk for ILD progression. Fibroblast activation protein (FAP) has gained interest as a biomarker to reflect fibrotic activity. As circulating FAP (cFAP) can be measured in blood, we aimed to investigate the value of cFAP in SSc-ILD.
Methods
cFAP concentrations were determined in plasma samples of 210 patients with systemic sclerosis (SSc) using an enzyme-linked immunosorbent assay. We compared cFAP in baseline and repeated longitudinal samples between SSc patients with (
n
= 63) and without ILD (
n
= 147). Furthermore, we investigated the correlation between cFAP and ILD progression at follow-up. In an exploratory analysis, we also investigated if cFAP was associated with other disease-related clinical features and all-cause mortality.
Results
cFAP levels were not different between SSc patients with- and without ILD, both at baseline (median 91.5 and 97.7 ng/mL respectively;
p
= 0.80) or during follow-up. Furthermore, we found no association between cFAP at baseline and ILD progression at 1, 2 and 5 years of follow-up. Notably, cFAP levels were elevated at baseline in patients with higher skin scores (mRSS ≥ 10 compared to mRSS < 10;
p
= 0.01). Finally, we did not find an association between cFAP and all-cause mortality at 5 and 10 years of follow-up.
Conclusion
In conclusion, cFAP does not seem useful as a biomarker in SSc-ILD. However, the association between cFAP and skin score deserves further investigation.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Analysis
/ Complications and side effects
/ Enzyme-linked immunosorbent assay
/ Enzymes
/ Female
/ Fibroblast activation protein
/ Humans
/ Lung Diseases, Interstitial - blood
/ Lung Diseases, Interstitial - diagnosis
/ Lung Diseases, Interstitial - etiology
/ Lung Diseases, Interstitial - mortality
/ Male
/ Medicine
/ Scleroderma, Systemic - blood
/ Scleroderma, Systemic - complications
/ Serine Endopeptidases - blood
/ Skin
